Shore Capital is delighted to have acted as Joint Broker and Joint Bookrunner for Destiny Pharma plc (AIM: DEST) on an up to £8m fundraise comprising of a Placing, Subscription and Open Offer.

Net proceeds of the Placing will allow the Company to complete final Phase 3 clinical trial preparation for NTCD-M3, its lead asset for the prevention of C. difficile infection recurrence, in conjunction with the collaboration and co-development agreement with Sebela Pharmaceuticals announced at the same time as the fundraising. The fundraising will also allow Destiny Pharma to continue to develop its other clinical and preclinical projects and will provide general working capital to strengthen its balance sheet

For further information please contact:  

Shore Capital +44 (0) 20 7408 4090

Corporate Advisory: Daniel Bush/James Thomas/Lucy Bowden

For Shore Capital media enquiries, please contact:  

Will Poulton: +44 (0)74 8038 3738